Artemis Medicare Services Q2 Profit Rises to Rs 31.10 Crore

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorIshaan Verma|Published at:
Artemis Medicare Services Q2 Profit Rises to Rs 31.10 Crore

Artemis Medicare Services reported a steady rise in Q2 revenue to Rs 311.04 crore, with net profit climbing to Rs 31.10 crore. Key growth driver includes the soft launch of a new 300-bed hospital in Raipur, expanding the firm's footprint in Chhattisgarh.

Artemis Medicare Services Reports Steady Q2 Growth

Revenue grew to Rs 311.04 crore from Rs 274.70 crore; Net profit increased to Rs 31.10 crore.

Reader Takeaway: Revenue growth remains healthy, but investors should watch if the new Raipur unit pressures short-term operating margins.

What just happened

Artemis Medicare Services has released its financial results for the quarter ended September 30, 2026. The consolidated revenue rose to Rs 311.04 crore, up from Rs 274.70 crore in the same period last year. Net profit after tax saw a modest gain, settling at Rs 31.10 crore compared to Rs 30.00 crore previously.

Why this matters

The company officially confirmed the soft launch of its 300-bed multi-super speciality hospital in Raipur, Chhattisgarh, which began operations in July 2026. This move marks a significant expansion in the hospital chain’s capacity. Investors are currently tracking how quickly this facility can contribute to the bottom line.

The backstory

The company maintains a consistent track record, with statutory auditors issuing an unmodified review conclusion for this quarter. Shareholders have also received a final dividend of Rs 0.45 per equity share for the financial year ended March 31, 2026, reflecting the company’s focus on steady capital returns.

What to track next

The primary focus for the coming quarters will be the occupancy ramp-up at the Raipur facility. Management will likely face scrutiny regarding the operational costs of this new site and whether it dilutes consolidated margins in the short term as the facility scales up.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.